title: Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia.
  
  
  METHODS
  This was a prospective, multicenter, consecutive, nonrandomized, interventional case series. The study included 34 eyes of 32 patients with choroidal neovascularization secondary to pathologic myopia; 13 eyes had previous photodynamic therapy, and 21 eyes had no previous treatment. The patients were followed for > or = 12 months. Best-corrected visual acuity, optical coherence tomography, and the presence of metamorphopsia were assessed monthly.
  
  
  RESULTS
  Mean visual acuity improved 8 letters from baseline to 12-month follow-up, and the difference was statistically significant (P < 0.001): 100% of the eyes lost <3 lines on the Early Treatment Diabetic Retinopathy Study chart, 24% of the eyes improved > or = 3 lines, 44% improved > or = 2 lines, 65% improved > or = 1 line, and 79% improved > or = 0 lines. Central retinal thickness decreased significantly from baseline to the 12-month follow-up (P < 0.01). A mean of 3.6 treatments were performed during the 12-month follow-up, and no systemic or ocular side effects were registered during that time.
  
  
  CONCLUSIONS
  One-year results of intravitreal ranibizumab for myopic choroidal neovascularization are very promising. Additional prospective studies are necessary to better determine long-term efficacy and safety.
authors.affiliation: Department of Ophthalmology, University Hospital of Coimbra, Coimbra, Portugal.
authors.forename: Rufino M
authors.initials: RM
authors.lastname: Silva
authors.forename: José M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Paulo
authors.initials: P
authors.lastname: Rosa
authors.forename: Angela
authors.initials: A
authors.lastname: Carneiro
authors.forename: João
authors.initials: J
authors.lastname: Nascimento
authors.forename: Luís F
authors.initials: LF
authors.lastname: Rito
authors.forename: M Luz
authors.initials: ML
authors.lastname: Cachulo
authors.forename: Fausto
authors.initials: F
authors.lastname: Carvalheira
authors.forename: Joaquim N
authors.initials: JN
authors.lastname: Murta
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D011446:Prospective Studies; D000069579:Ranibizumab; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab